Preventing complications and cancer in people with cirrhosis
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network
This project tests whether close clinical monitoring, detailed biospecimen collection, and long-term statin treatment can help people with compensated cirrhosis avoid liver failure and liver cancer.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11169668 on NIH RePORTER |
What this research studies
I would join a group of patients with compensated cirrhosis (including NASH, alcohol-related, cholestatic, and cryptogenic types) who give clinical information, blood samples, and behavioral data. The team will follow us over time to build models that predict who is likely to worsen and to validate cirrhosis patterns using electronic health records. They will also compare outcomes linked to different lipid-lowering drugs in real-world data and test whether long-term statin use prevents decompensation and hepatocellular carcinoma. The network combines in-person study sites and a larger virtual EHR cohort to speed enrollment and confirm findings.
Who could benefit from this research
Good fit: Adults with compensated cirrhosis (NASH, alcohol-related, cholestatic, or cryptogenic) who can provide clinical data, biospecimens, and follow-up information are the best candidates.
Not a fit: People with already decompensated cirrhosis, those with contraindications to statins, or those unable to provide follow-up data are less likely to benefit from this project.
Why it matters
Potential benefit: If successful, this work could identify who is most at risk of liver complications and show whether statins or other lipid-lowering drugs can safely reduce progression to liver failure and cancer.
How similar studies have performed: Observational studies and retrospective analyses have suggested statins may lower complications in liver disease, but strong randomized trial evidence is limited and this combined cohort-plus-trial approach is relatively novel.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Brown, Robert S — Weill Medical Coll of Cornell Univ
- Study coordinator: Brown, Robert S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.